Research & Development: Page 2


  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    By Oct. 27, 2023
  • 2023 Red Jacket header
    Image attribution tooltip

    Photo illustration: Industry Dive

    Image attribution tooltip

    The 2023 Red Jacket honorees

    This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

    By Oct. 27, 2023
  • women's health Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Women's health

    As women’s health investments explode, major opportunities for growth remain.

    By PharmaVoice staff
  • Ken Getz, professor and executive director, Tufts Center for the Study of Drug Development
    Image attribution tooltip

    Industry Dive; Getty Images

    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Ken Getz, a champion of clinical trials

    Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.

    By Alexandra Pecci • Oct. 27, 2023
  • Dr. Mark Goldberg, CEO and chairman, Allucent
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Dr. Mark Goldberg, a clinical innovator

    Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

    By Alexandra Pecci • Oct. 27, 2023
  • vaccine ampoules on red
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Cidara’s J&J-partnered immunotherapy could target flu and cancer

    On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

    By Alexandra Pecci • Oct. 26, 2023
  • Patient group
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

    “They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

    By Kelly Bilodeau • Oct. 25, 2023
  • Antibodies autoimmune disease
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    An ‘inverse vaccine’ takes aim at autoimmune diseases

    Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

    By Kelly Bilodeau • Oct. 23, 2023
  • PV100 category header
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Clinical trial gurus

    Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.

    By Oct. 19, 2023
  • rainforest pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

    A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

    By Kelly Bilodeau • Oct. 17, 2023
  • Aging clock melting
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Has the science of anti-aging caught up with the dream of a longer life?

    Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

    By Kelly Bilodeau • Oct. 16, 2023
  • A close up a cell with a large screen in the background displaying a injection needle.
    Image attribution tooltip

    Gregor Fischer/DPA/Newscom

    Image attribution tooltip
    Deep Dive

    A decade later, biotech’s CRISPR revolution is still going strong

    Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

    By Gwendolyn Wu , , Oct. 12, 2023
  • Alnylam Pharmaceuticals CEO Yvonne Greenstreet
    Image attribution tooltip
    Permission granted by Alnylam/Yvonne Greenstreet
    Image attribution tooltip

    Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

    Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

    By Oct. 12, 2023
  • Image attribution tooltip

    Permission granted by Mike Rea.

    Image attribution tooltip
    Q&A

    5 minutes with — IDEA Pharma’s Mike Rea

    The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

    By Oct. 11, 2023
  • pediatric cancer concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    To close the pediatric innovation gap, this biotech has to think differently

    Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

    By Alexandra Pecci • Oct. 11, 2023
  • The logo of Google Cloud is seen at the 2023 Hannover Messe industrial trade fair on April 17, 2023 in Hanover, Germany.
    Image attribution tooltip
    Alexander Koerner / Stringer via Getty Images
    Image attribution tooltip

    Google bets on AI in the life sciences as ‘technology for a purpose’

    A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

    By Alexandra Pecci • Oct. 10, 2023
  • bone study in space
    Image attribution tooltip
    Permission granted by Dr. Chia Soo
    Image attribution tooltip

    Research in space yields clues about boosting bone health on Earth

    A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.

    By Kelly Bilodeau • Oct. 10, 2023
  • Mechanical hand reaching toward clear pill against a backdrop of numerical code
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Tech wizards

    The leaders paving the way to pharma’s future with state-of-the-art digital solutions.

    By Karissa Waddick • Oct. 9, 2023
  • dna tube
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    A biotech ‘tuning’ the genome for a potentially safer gene therapy

    Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

    By Kelly Bilodeau • Oct. 9, 2023
  • a unicorn chess piece sits on top of a stack of coins
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where have all the unicorns gone? A look at 4 billion-dollar biotechs

    Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.

    By Alexandra Pecci • Oct. 3, 2023
  • Puzzle of the human heart and doctor hand with the missing piece of puzzle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The ALS therapy keeping the human pig heart transplant pumping

    Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.

    By Kelly Bilodeau • Oct. 2, 2023
  • Jynneos Bavarian Nordic vaccine monkeypox
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip
    Q&A

    Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

    Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.

    By Karissa Waddick • Sept. 27, 2023
  • Growing plant in low poly wireframe style
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

    The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

    By Alexandra Pecci • Sept. 26, 2023
  • AI human
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Do humans have a place in pharma’s AI future?

    From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

    By Sept. 26, 2023
  • Old people silhouette
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Elderly exclusion: Clinical trials still fall short enrolling older adults

    Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.

    By Kelly Bilodeau • Sept. 25, 2023
  • An open peanut shell sits on top a pile of other peanut shells.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Profile

    Three years after an FDA rejection, DBV sees a path for its peanut patch

    Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

    By Karissa Waddick • Sept. 22, 2023